(Q42914479)

11 November 2017

title

Remodelling of the heart and vessels in experimental hypertension: advances in protection (English)

1 reference

11 November 2017

1

Fedor Simko

1 reference

11 November 2017

2

Olga Pechanova

1 reference

11 November 2017

Olga Pechanova

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20823710

8 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20823710

8 July 2024

publication date

1 September 2010

1 reference

full work available at URL

11 November 2017

http://journals.lww.com/00004872-201009001-00001

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

8 July 2024

published in

Journal of Hypertension

1 reference

11 November 2017

volume

28 Suppl 1

1 reference

11 November 2017

page(s)

S1-6

1 reference

A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension

11 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Statins: a perspective for left ventricular hypertrophy treatment

8 July 2024

2

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Cardioreparation in hypertensive heart disease

8 July 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

From inflammation to fibrosis: a stiff stretch of highway

8 July 2024

4

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy

8 July 2024

6

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Regression of chronic L -NAME-treatment-induced left ventricular hypertrophy: effect of captopril

8 July 2024

10

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients

8 July 2024

12

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Physiologic and pathologic myocardial hypertrophy--physiologic and pathologic regression of hypertrophy?

8 July 2024

13

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

A welcome debate on how to measure the left ventricular mass

8 July 2024

14

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angioten

8 July 2024

15

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Hypertensive myocardial fibrosis.

8 July 2024

16

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

8 July 2024

17

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Urinary 6-sulphatoxymelatonin, an index of pineal function in the rat.

8 July 2024

19

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Continuous light exposure and sympathectomy suppress circadian rhythm of blood pressure in rats

8 July 2024

20

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Experimental hypertension in pinealectomized rats

8 July 2024

22

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Effects of pinealectomy and exogenous melatonin on rat hearts

8 July 2024

23

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of NG-nitro-L-arginine-methyl ester hypertensive rats

8 July 2024

25

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Melatonin interactions with blood pressure and vascular function during L-NAME-induced hypertension

8 July 2024

26

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension

8 July 2024

27

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment

8 July 2024

28

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Melatonin as a potential antihypertensive treatment

8 July 2024

29

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Chronotherapy beyond blood pressure reduction?

8 July 2024

30

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Recent trends in hypertension treatment: perspectives from animal studies.

8 July 2024

31

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

The circadian melatonin rhythm and its modulation: possible impact on hypertension

8 July 2024

32

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men

8 July 2024

33

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart

8 July 2024

35

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Cardiovascular diseases: protective effects of melatonin

8 July 2024

36

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats.

8 July 2024

37

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Myocardial remodeling in low-renin hypertension: molecular pathways to cellular injury in relative aldosteronism

8 July 2024

38

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Hyperparathyroidism and the calcium paradox of aldosteronism

8 July 2024

39

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Causes and consequences of zinc dyshomeostasis in rats with chronic aldosteronism

8 July 2024

40

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Temporal responses to intrinsically coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria during aldosteronism

8 July 2024

41

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Macro- and micronutrient dyshomeostasis in the adverse structural remodelling of myocardium

8 July 2024

42

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Aldosteronism and a proinflammatory vascular phenotype: role of Mg2+, Ca2+, and H2O2 in peripheral blood mononuclear cells

8 July 2024

43

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Metabolomics in angiotensin II-induced cardiac hypertrophy

8 July 2024

44

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Calcium, calpains, and cardiac hypertrophy: a new link

8 July 2024

45

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB.

8 July 2024

46

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Targeted deletion of nuclear factor kappaB p50 enhances cardiac remodeling and dysfunction following myocardial infarction

8 July 2024

47

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Silencing MR-1 attenuates inflammatory damage in mice heart induced by AngII

8 July 2024

48

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

NF-kappaB activation is required for adaptive cardiac hypertrophy.

8 July 2024

49

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Regulating the regulator: NF-kappaB signaling in heart

8 July 2024

50

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Heart failure and angiotensin converting enzyme inhibition: problems and perspectives

8 July 2024

51

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Angiotensin AT2 receptors: cardiovascular hope or hype?

8 July 2024

52

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle

8 July 2024

53

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

The past, present and future of angiotensin II type 2 receptor stimulation

8 July 2024

54

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Adapter proteins and promoter regulation of the angiotensin AT2 receptor--implications for cardiac pathophysiology

8 July 2024

55

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Effect of angiotensin II type 1 receptor blockade on cardiac remodeling in angiotensin II type 2 receptor null mice

8 July 2024

56

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis

8 July 2024

57

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB.

8 July 2024

58

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

LA419, a novel nitric oxide donor, prevents cardiac remodeling via the endothelial nitric oxide synthase pathway: NO donors as a means of antiremodeling

8 July 2024

61

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

2007 Guidelines for the Management of Arterial Hypertension

8 July 2024

62

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Should elderly heart failure patients be treated with beta-blockade therapy?

8 July 2024

63

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

A novel anti-ischemic nitric oxide donor (LA419) reduces thrombogenesis in healthy human subjects

8 July 2024

64

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation.

8 July 2024

65

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

Cardiac hypertrophy as a target of antihypertensive therapy

8 July 2024

66

1 reference

https://api.crossref.org/works/10.1097/01.HJH.0000388487.43460.DB

8 July 2024

Identifiers

1 reference

11 November 2017

1 reference